Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

In September, the use of a Sanofi immuno-inflammatory medicine to treat chronic obstructive pulmonary disease (COPD) was ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Sanofi and Regeneron, meanwhile, have other irons in the COPD fire, notably itepekimab, an antibody that inhibits IL-33 that could be used in a broader spectrum of patients. It is in two phase 3 ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights ...